Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,
我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声:
例
、词
均由互联网资源自动生成,部
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症。
明:以上例
、词性分类
联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内
代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
:
上例
、词性
由互联网资源自动生成,部
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声:
例
、词
均由互联网资源自动生成,部
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药。
:以上例
、词性分
互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观
;
现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:以上例、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若
题,欢迎向我们指正。